New Pneumococcal Serotype 15D

Pimenta, Fabiana Cristina; Moiane, Benild; Gertz, Robert E.; Chochua, Sopio; Vagnone, Paula M Snippes; Lynfield, Ruth; Sigaùque, Betuel; Carvalho, Maria da Glória; Beall, Bernard

doi:10.1128/jcm.00329-21

Cited by 16 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The primary virulence factor of pneumococci is the polysaccharide capsule 3 and currently available pneumococcal vaccines are all based on capsular polysaccharides as the antigen. While there have been over 100 capsular types (serotypes) described 4 , 5 , marketed vaccines target only a subset of ten to twenty-three serotypes (24 serotypes in total). Pneumococcal conjugate vaccines (PCV) recommended for children 2 , target ten (PCV10) and thirteen (PCV13) serotypes common in paediatric disease prior to PCVs introduction.…”

Section: Introductionmentioning

confidence: 99%

Pneumococcal carriage in unvaccinated children at the time of vaccine implementation into the national immunization program in Poland

Wróbel-Pawelczyk

Ronkiewicz

Wanke-Rytt

et al. 2022

Sci Rep

View full text Add to dashboard Cite

We investigated pneumococcal carriage among unvaccinated children under five years of age at a time when the conjugate polysaccharide vaccine (PCV) was introduced in Poland into the national immunization program (NIP). Paired nasopharyngeal swab (NPS) and saliva samples collected between 2016 and 2020 from n = 394 children were tested with conventional culture and using qPCR. The carriage rate detected by culture was 25.4% (97 of 394), by qPCR 39.1% (155 of 394), and 40.1% (158 of 394) overall. The risk of carriage was significantly elevated among day care center attendees, and during autumn/winter months. Among isolates cultured, the most common serotypes were: 23A, 6B, 15BC, 10A, 11A. The coverage of PCV10 and PCV13 was 23.2% (23 of 99) and 26.3% (26 of 99), respectively. Application of qPCR lead to detection of 168 serotype carriage events, with serogroups 15, 6, 9 and serotype 23A most commonly detected. Although the highest number of carriers was identified by testing NPS with qPCR, saliva significantly contributed to the overall number of detected carriers. Co-carriage of multiple serotypes was detected in 25.3% (40 of 158) of carriers. The results of this study represent a baseline for the future surveillance of effects of pneumococcal vaccines in NIP in Poland.

show abstract

Section: Introductionmentioning

confidence: 99%

Pneumococcal carriage in unvaccinated children at the time of vaccine implementation into the national immunization program in Poland

Wróbel-Pawelczyk

Ronkiewicz

Wanke-Rytt

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The expression of CPS is detrimental for biofilm formation 13 , 14 . At least 101 different pneumococcal serotypes are known demonstrating the high variability of CPS within this pathogen 15 , 16 . The serotype 19A, which is a good biofilm former in vitro, is also a good colonizer with a significant incidence of IPD 9 – 11 , 17 , 18 .…”

Section: Introductionmentioning

confidence: 99%

Clearance of mixed biofilms of Streptococcus pneumoniae and methicillin-susceptible/resistant Staphylococcus aureus by antioxidants N-acetyl-l-cysteine and cysteamine

Sempere

Llamosí

Román

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Biofilm-associated infections are of great concern because they are associated with antibiotic resistance and immune evasion. Co-colonization by Staphylococcus aureus and Streptococcus pneumoniae is possible and a threat in clinical practice. We investigated the interaction between S. aureus and S. pneumoniae in mixed biofilms and tested new antibiofilm therapies with antioxidants N-acetyl-l-cysteine (NAC) and cysteamine (Cys). We developed two in vitro S. aureus–S. pneumoniae mixed biofilms in 96-well polystyrene microtiter plates and we treated in vitro biofilms with Cys and NAC analyzing their effect by CV staining and viable plate counting. S. pneumoniae needed a higher proportion of cells in the inoculum and planktonic culture to reach a similar population rate in the mixed biofilm. We demonstrated the effect of Cys in preventing S. aureus biofilms and S. aureus–S. pneumoniae mixed biofilms. Moreover, administration of 5 mg/ml of NAC nearly eradicated the S. pneumoniae population and killed nearly 94% of MSSA cells and 99% of MRSA cells in the mixed biofilms. The methicillin resistance background did not change the antioxidants effect in S. aureus. These results identify NAC and Cys as promising repurposed drug candidates for the prevention and treatment of mixed biofilms by S. pneumoniae and S. aureus.

show abstract

“…This bacterium has a genome of 2.16 Mbps, encoding 2,236 open reading frames ( Tettelin, H. et al., 2001 ). Its genome is highly variable due to its natural ability to take up DNA through natural transformation ( Johnsborg and Håvarstein, 2009 ; Andam and Hanage, 2015 ) and currently, 101 capsular serotypes of S. pneumoniae have been identified ( Ganaie et al., 2020 ; Pimenta et al., 2021 ).…”

Section: Streptococcus Pneumoniae Pathogenesis and Current V...mentioning

confidence: 99%

“…Streptococcus pneumoniae ( S. pneumoniae ) is an opportunistic pathogen that colonizes the human nasopharynx ( Henriques-Normark and Tuomanen, 2013 ; Weiser et al., 2018a ). S. pneumoniae is a highly heterogeneous bacterium with more than 100 serotypes differentiated by their polysaccharide capsule composition ( Pimenta et al., 2021 ). S. pneumoniae is a clinically relevant bacterium as is the bacterial leading cause of respiratory infections such as pneumonia, meningitis, otitis media, and other diseases in children under five years old and the elderly in the community ( O’Brien et al., 2009 ; Wahl et al., 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Non-capsular based immunization approaches to prevent Streptococcus pneumoniae infection

Silva

Vázquez

Campusano

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Streptococcus pneumoniae is a Gram-positive bacterium and the leading cause of bacterial pneumonia in children and the elderly worldwide. Currently, two types of licensed vaccines are available to prevent the disease caused by this pathogen: the 23-valent pneumococcal polysaccharide-based vaccine and the 7-, 10, 13, 15 and 20-valent pneumococcal conjugate vaccine. However, these vaccines, composed of the principal capsular polysaccharide of leading serotypes of this bacterium, have some problems, such as high production costs and serotype-dependent effectiveness. These drawbacks have stimulated research initiatives into non-capsular-based vaccines in search of a universal vaccine against S. pneumoniae. In the last decades, several research groups have been developing various new vaccines against this bacterium based on recombinant proteins, live attenuated bacterium, inactivated whole-cell vaccines, and other newer platforms. Here, we review and discuss the status of non-capsular vaccines against S. pneumoniae and the future of these alternatives in a post-pandemic scenario.

show abstract

New Pneumococcal Serotype 15D

Abstract: The pneumococcal serogroup 15 comprises 4 capsular polysaccharide serotypes (15A, 15B, 15C, 15F) that collectively account for an impactful disease burden (1,2).…

Cited by 16 publications

References 8 publications

Pneumococcal carriage in unvaccinated children at the time of vaccine implementation into the national immunization program in Poland

Pneumococcal carriage in unvaccinated children at the time of vaccine implementation into the national immunization program in Poland

Clearance of mixed biofilms of Streptococcus pneumoniae and methicillin-susceptible/resistant Staphylococcus aureus by antioxidants N-acetyl-l-cysteine and cysteamine

Non-capsular based immunization approaches to prevent Streptococcus pneumoniae infection

Contact Info

Product

Resources

About